17,261 trials
Asthma
Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) — 2.139; 2.071; 2.187; 2.162 Liters
Alzheimer's Type Dementia
Primary: Maximum Observed Plasma Concentration (Cmax) of E2020 on Visits 2 and 3 — 126.503; 97.006; 127.335; 66.081 ng/mL
Lymphoma
Primary: Number of Progression Events in 2 Years. — 41; 1; 46; 8 Event
Cystic Fibrosis
Primary: Part A: Change From Baseline in Total Ventilation Defect Defined by Hyperpolarized Helium 3 Magnetic Resonance Imaging (3He-MRI) at Day 43 — -8.20 percentage of total…
Male Hypogonadism · Muscle Atrophy · Sarcopenia
Primary: 1 Repetition Maximum (1-RM) Strength Testing — 129.1; 109.4; 137.2; 118.8 kg — p=<0.001
HIV Infection
Primary: Percentage of Participants With at Least One Clinical Adverse Experience — 0.0; 42.9 Percentage of participants
Squamous Cell Carcinoma of the Head and Neck Cancer
Primary: Progression-free Survival (PFS) Time: Independent Read Assessments — 1.5; 1.9 months — p=0.793
Cerebral Infarction
Primary: Number of Participants Experiencing Non-Major Adverse Cardiac Events (Non-MACE) — 27; 27; 22 Participants
Uterine Cervical Dysplasia
Primary: Injection Pain Score (Mean) — 25; 19 units on a scale — p=.13
Hepatitis C
Primary: Change From Baseline in log10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels — -2.02; 0.16; -3.43; -2.71 log10 IU/mL
Gout
Primary: Serum Uric Acid — -16.0; -9.9; -9.5 percent change
Secondary Hypogonadism
Primary: Change in Total Morning Testosterone — -16.9; 253.7; 258.5; 197.3 ng/dL
Asthma
Primary: Mean Score on the Family Asthma Management System Scale (FAMSS) — 4.9; 4.1 units on a scale — p=0.23
Amenorrhea
Primary: Induction Amenorrhea — 2; 9; 6; 8 participants
Acellular Pertussis · Hepatitis B · Haemophilus Influenzae Type b
Primary: Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies — 81; 82; 90; 81 Participants